News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Tactical long recommended on Par Pacific (PARR) to ride refining margin strength.
  • Entry $81.32, stop $72.00, target $100.00.
  • Analyst cites PARR's high cash flow.
  • Company reported improved results.
  • Balance-sheet repair reduced leverage.
  • Risk: snap-back in fuel spreads.

Latest Articles

Aptevo Shares Drop Sharply Despite Strong TP53 AML Trial Readout

Aptevo Shares Drop Sharply Despite Strong TP53 AML Trial Readout

Aptevo Therapeutics shares plunged in pre-market trading despite the company reporting a high clinical benefit rate from its mipletamig triplet regimen in frontline acute myeloid leukemia patients with TP53 mutations. The decline reflects a 'sell the news' reaction, a large potential share overhang from recent financings, and persistent bearish tec…

IFM Publishes Six AI Models with Complete Development Artifacts

IFM Publishes Six AI Models with Complete Development Artifacts

Abu Dhabi-based research institute IFM published six artificial intelligence models and provided the full suite of development materials used to create them. The K2 Horizon release includes model weights, training data, code, methodologies and intermediate checkpoints, which IFM says will allow researchers to retrace the models' development and rep…

Alcon: Position for a Re-Rate as Ophthalmology Demand and Sentiment Align

Alcon: Position for a Re-Rate as Ophthalmology Demand and Sentiment Align

Alcon ($ALC) offers a tactical long setup around $71.63. The company sits in a structurally growing ophthalmology market, trades below its 52-week high, and exhibits solid balance-sheet metrics that reduce downside risk. Combined with outsized short interest and recent institutional buying, there’s a credible path to a re-rating over the next 45 tr…

Buy GLUE: Well-Funded Molecular Glue Pipeline with Near-Term Catalysts

Buy GLUE: Well-Funded Molecular Glue Pipeline with Near-Term Catalysts

Monte Rosa Therapeutics (GLUE) trades around $14.27 with a market cap near $1.21B. The stock combines high clinical binary risk with a clean balance sheet after a $300M raise and a $120M upfront collaboration with Novartis. For disciplined traders willing to stomach biotech volatility, a long position sized carefully offers compelling asymmetric up…

Broadcom Looks Undervalued at 19x 2027 – A Tactical Long

Broadcom Looks Undervalued at 19x 2027 – A Tactical Long

Broadcom (AVGO) is a hybrid semiconductor-software cash machine that the market is currently valuing at roughly 19x 2027 earnings. That multiple understates the company’s recurring software margin profile, cash generation and buyback optionality. We recommend a long trade with a clear entry, stop and target tied to improving fundamentals and multip…

Volaris Reports August 2026 Traffic Results: Load Factor of 84%

Volaris Reports August 2026 Traffic Results: Load Factor of 84%

Volaris, an ultra-low-cost carrier operating in Mexico, the US, Central and South America, reported a 15.8% increase in available seat miles and a 15.4% rise in revenue passenger miles for August 2026. The airline transported 3.2 million passengers with a consolidated load factor slightly down by 0.3 percentage points to 84.4%, reflecting strong su…

MediaAlpha Announces Chief Financial Officer Transition

MediaAlpha Announces Chief Financial Officer Transition

MediaAlpha, Inc. announced that Pat Thompson will step down as CFO effective October 1, 2026, with Tigran Sinanyan returning to the role. The company expects third quarter 2026 financial results to be at or above the high end of previous guidance. Sinanyan's deep knowledge of the business and prior experience as CFO positions MediaAlpha to sustain …

Palisade Bio to Participate in Upcoming Investor Conferences

Palisade Bio to Participate in Upcoming Investor Conferences

Palisade Bio, a clinical-stage biopharmaceutical company focused on developing prodrugs to treat inflammatory and fibrotic diseases, announced its participation in three major healthcare investor conferences in September 2026, including Wells Fargo, Morgan Stanley, and H.C. Wainwright events. Management will engage in investor meetings and fireside…